Hepatitis C

Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Influenza Multiplex PCR Test

Retrieved on: 
Thursday, March 7, 2024

SALT LAKE CITY, March 7, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the "JV"), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization ("CDSCO") in India to manufacture and sell its SARAPLEX™ Influenza Multiplex (IFM) Test Kit to clinical laboratories as an in vitro diagnostic ("IVD") for the detection and differentiation of Influenza A and Influenza B.

Key Points: 
  • Co-Primers utilize a unique design architecture to combat common issues with real-time PCR that can lead to inaccurate results, specifically primer dimer propagation, and which are magnified in multiplex reactions.
  • "The importance of accurate, reliable PCR testing at the high-throughput clinical laboratory level remains critical," remarked Dwight Egan, CEO of Co-Diagnostics.
  • *The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.
  • The Co-Dx PCR Pro instrument and Co-Dx COVID-19 Test are currently under review by the FDA.

Care Resource Receives $50,000 from Advance Auto Parts Foundation to Deliver Healthcare Services to Under-Resourced Communities in Broward County

Retrieved on: 
Tuesday, March 5, 2024

FORT LAUDERDALE, Fla., March 5, 2024 /PRNewswire/ -- Care Resource has launched a new mobile health unit, made possible by a generous $50,000 donation from the Advance Auto Parts Foundation.

Key Points: 
  • FORT LAUDERDALE, Fla., March 5, 2024 /PRNewswire/ -- Care Resource has launched a new mobile health unit, made possible by a generous $50,000 donation from the Advance Auto Parts Foundation.
  • This mobile health unit marks a significant advancement in the health center's mission to expand access to services in under-resourced communities throughout South Florida.
  • "Every person deserves the opportunity for a full, healthy life, which is why community health is a key pillar for our Advance Auto Parts Foundation.
  • By expanding health care services through mobile health units, Care Resource can further provide communities with the right care, at the right time, in the right place.

Longtime Gilead Commercial Executive Joins IntegriChain as Chairman of the Board

Retrieved on: 
Wednesday, February 28, 2024

PHILADELPHIA, Feb. 28, 2024 /PRNewswire/ -- IntegriChain, delivering pharma's only comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, today announced the appointment of Jim Meyers, a highly experienced pharmaceutical commercialization executive, as Chairman of the Board.

Key Points: 
  • PHILADELPHIA, Feb. 28, 2024 /PRNewswire/ -- IntegriChain, delivering pharma's only comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, today announced the appointment of Jim Meyers, a highly experienced pharmaceutical commercialization executive, as Chairman of the Board.
  • "We are thrilled to have an industry icon of Jim's caliber lead our board as our company matures," said Josh Halpern , Co-Founder and CEO of IntegriChain.
  • The Board is enthusiastic about adding further expertise to build upon the Company's leadership and support the expansion of its product offerings," said Daniel Berglund, Co-Head of Healthcare, Nordic Capital Investment Advisors and Board Member of IntegriChain.
  • "I am honored to join the IntegriChain board at this pivotal moment," said Meyers.

Government of Canada supports community-based projects addressing HIV, Hepatitis C, and other sexually transmitted and blood-borne infections

Retrieved on: 
Friday, February 23, 2024

However, these infections remain a significant public health concern in Canada, especially among Indigenous, 2SLGBTQ+, and other equity-deserving communities.

Key Points: 
  • However, these infections remain a significant public health concern in Canada, especially among Indigenous, 2SLGBTQ+, and other equity-deserving communities.
  • Today's funding includes more than $12 million through the CAF, which will support 15 community-based interventions to address HIV, hepatitis C and other STBBI.
  • In 2022, the Government of Canada invested $106.4 million to help address STBBI across Canada.
  • Through the HIV and Hepatitis C Community Action Fund, the Public Health Agency of Canada (PHAC) invests $26.4 million annually to support time-limited projects (up to 5 years) across Canada to address HIV, hepatitis C and other sexually transmitted infections (e.g., chlamydia, gonorrhea, syphilis).

Gilead Named One of America’s Most JUST Companies by JUST Capital and CNBC

Retrieved on: 
Friday, February 9, 2024

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company has been named one of America’s Most JUST Companies.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company has been named one of America’s Most JUST Companies.
  • The ranking, presented by JUST Capital and CNBC, reflects Gilead’s longstanding commitment to operate responsibly by prioritizing stakeholder engagement – including with the patients and communities the company serves, employees and shareholders – while working to create a healthier world for all people.
  • Gilead was recognized on the top 100 list and ranked fifth in the Pharmaceuticals and Biotech industry.
  • Learn more about Gilead’s commitment to ESG at https://www.gilead.com/purpose/esg .

Shionogi Strengthens Regulatory Leadership with the Appointment of Dr. Ramón Polo as Senior Vice President, Head of Regulatory Affairs

Retrieved on: 
Monday, February 5, 2024

Shionogi Inc., a U.S. subsidiary of Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereinafter “Shionogi”), announced the appointment of Ramón Polo, MBA, PharmD, Ph.D. as Senior Vice President, Head of Regulatory Affairs.

Key Points: 
  • Shionogi Inc., a U.S. subsidiary of Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereinafter “Shionogi”), announced the appointment of Ramón Polo, MBA, PharmD, Ph.D. as Senior Vice President, Head of Regulatory Affairs.
  • He joins Shionogi Inc. from Johnson & Johnson, where he served as the Vice President, Head of Infectious Diseases, Vaccines & Global Public Health Regulatory Affairs.
  • Prior to this, Dr. Polo led the development strategy of treatments for influenza, RSV and hepatitis C at Janssen Pharmaceutical Companies of Johnson & Johnson.
  • Dr. Polo received his PharmD, Master of Science and Ph.D. in Clinical Biochemistry from the Complutense University of Madrid in Spain.

Blue Faery Continues Its Love Your Liver Campaign During Black History Month

Retrieved on: 
Thursday, February 1, 2024

BIRMINGHAM, Ala., Feb. 1, 2024 /PRNewswire/ -- Black/African Americans are 50% more likely to get liver cancer than the general population, and incidence rates are climbing. The Love Your Liver campaign provides community members with convenient opportunities to learn more about their unique liver cancer risks and how to actively manage them. Type 2 diabetes and hepatitis C can both lead to liver cancer, so those in the Black/African American community who currently have or previously had one or both of those diseases are at higher risk for liver cancer. Both type 2 diabetes and hepatitis C are preventable and treatable, so education and early detection are vital to improving survival rates.

Key Points: 
  • Blue Faery is pleased to announce that its annual liver disease and cancer awareness campaign will continue in 2024 during Black History Month.
  • The Love Your Liver campaign provides community members with convenient opportunities to learn more about their unique liver cancer risks and how to actively manage them.
  • Love Your Liver Live, a Black History Month Community Event series, kicks off on February 22, 2024, at 7 p.m.
  • Blue Faery has many educational and advocacy programs, including Love Your Liver, The Truth About Liver Cancer, and You and Liver Cancer.

United States Connected Drug Delivery Devices Markets, Competition, Forecasts & Opportunities, 2028F - ResearchAndMarkets.com

Retrieved on: 
Friday, December 15, 2023

Improvement in the quality of patient care and compliance and the changing healthcare infrastructure is expected to boost the United States connected drug delivery devices market growth.

Key Points: 
  • Improvement in the quality of patient care and compliance and the changing healthcare infrastructure is expected to boost the United States connected drug delivery devices market growth.
  • The segment is anticipated to dominate the United States connected drug delivery devices market in the next five years.
  • Also, the awareness regarding the benefits of connected systems over the traditional drug delivery system with improved patient response is expected to accelerate the growth of the United States connected drug delivery devices market.
  • Company Profiles: Detailed analysis of the major companies present in the United States connected drug delivery devices market.

Iris House to Host Fresh Market Food Bank

Retrieved on: 
Thursday, December 14, 2023

“We will be providing fresh produce to members of the community as they prepare for the holidays,” said Ingrid Floyd, Executive Director of Iris House.

Key Points: 
  • “We will be providing fresh produce to members of the community as they prepare for the holidays,” said Ingrid Floyd, Executive Director of Iris House.
  • Iris House’s Plainfield site eventually will house a new, state-of-the-art AHF Healthcare Center providing cutting-edge medical care and services to patients regardless of ability to pay and will also feature an AHF Pharmacy Access Center.
  • Iris House saves lives through comprehensive support, prevention and education services for women, families, and underserved populations affected by HIV/AIDS and other health disparities in a safe, family-centered environment by passionate, professional and culturally competent staff.
  • Iris House was named for early HIV Activist Iris De La Cruz, whose passion for our cause was instrumental in establishing our programs.

The CHOICE Institute at the University of Washington Partners With Komodo Health To Drive Critical Health Economic and Outcomes Research

Retrieved on: 
Monday, December 11, 2023

The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute at the University of Washington’s School of Pharmacy is joining forces with Komodo Health as its data and technology partner to drive comparative outcomes and cost-effectiveness research and analytics.

Key Points: 
  • The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute at the University of Washington’s School of Pharmacy is joining forces with Komodo Health as its data and technology partner to drive comparative outcomes and cost-effectiveness research and analytics.
  • The CHOICE Institute envisions using Komodo’s technology to unlock high-quality insights into healthcare utilization, costs, and outcomes in the United States, working toward its vision of generating knowledge to improve individual and population health.
  • Komodo Health is the technology partner of choice for academic researchers of health economics and outcomes research (HEOR) and expediting the production of critical research-grade evidence using the most comprehensive and representative data available.
  • Academic institutions continue to be the bedrock of healthcare research, driving innovative HEOR that impacts drug development, market access, and, ultimately, patient outcomes.